

Invitation to a webcast: adapting and acting in response to the Covid-19 crisis

In this unprecedented situation, MedinCell has adapted to protect its collaborators, ensure the continuity of its strategic activities, and launch a research project dedicated to Covid-19

Euronext: MEDCL • Montpellier - France • April 20, 2020 - 5:45 pm CEST

The webcast will cover MedinCell's latest operational developments, as well as the internal situation related to the pandemic, and will be the occasion to answer your questions.

The event, accessible only by computer from the following link, <u>https://invest.medincell.com/fr/conference/</u>, will be held on Thursday, April 23, 2020:

- at 1 pm cest in French
- at 3pm cest in English

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO[®] technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO[®] technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

Contacts

MedinCell David Heuzé Head of Communication david.heuze@medincell.com +33 (0)6 83 25 21 86 NewCap Louis-Victor Delouvrier Investor relations medincell@newcap.eu +33 (0)1 44 71 94 94 NewCap Nicolas Merigeau Media relations medincell@newcap.eu +33 (0)1 44 71 94 94